Sailong Pharmaceutical Group (002898.SZ): Net loss of 1.0385 million yuan in the first quarter.

Gelonghui, April 25th丨Sailong Pharmaceutical Group (002898.SZ) announced the Q1 report for 2025, with revenue of 54.0868 million yuan, a year-on-year decrease of 22.16%; Net income attributable to shareholders of the listed company was -1.0385 million yuan; Net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -1.1062 million yuan; Basic EPS was -0.0059 yuan.

Gelonghui FinanceApr 24 12:20 ET

Cailong Pharmaceuticals: First Quarter Report 2025

SZSIApr 24 12:00 ET · Announcements

Cailong Pharmaceuticals: 2024 Annual Report Summary

SZSIApr 24 12:00 ET · Announcements

Cailong Pharmaceuticals: 2024 Annual Report

SZSIApr 24 12:00 ET · Announcements

Sailong Pharmaceutical Group (002898.SZ): Currently, no antiviral drugs specifically targeting norovirus are being produced.

Gelonghui April 22丨Sailong Pharmaceutical Group (002898.SZ) stated on the interactive platform that the company is currently not producing antiviral drugs specifically targeting norovirus.

Gelonghui FinanceApr 22 03:01 ET

Sailong Pharmaceutical Group (002898.SZ): The company currently has no export business.

Gelonghui April 16丨Sailong Pharmaceutical Group (002898.SZ) stated on the interactive platform that the company has no export business for the time being, and specific situations can be monitored through the company's regular reports.

Gelonghui FinanceApr 16 03:03 ET